Overview

• Starting June 23, any physician will be able to initiate and renew prescriptions for Wegovy and Mounjaro in France
• Wegovy (semaglutide) and Mounjaro (tirzepatide) are GLP-1 receptor agonists approved as second-line obesity therapies
• These medications must be used alongside a hypocaloric diet and regular physical activity and are not intended for aesthetic weight loss
• Treatment costs can reach €300 per month and remain entirely out of pocket under France’s current reimbursement rules
• The ANSM will maintain heightened surveillance of adverse effects and other risks associated with these obesity drugs